Creative Planning Has $910,000 Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

Creative Planning boosted its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 57.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,209 shares of the company’s stock after purchasing an additional 6,674 shares during the period. Creative Planning’s holdings in Biohaven were worth $910,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Redwood Wealth Management Group LLC acquired a new position in Biohaven during the second quarter valued at approximately $61,000. Elkhorn Partners Limited Partnership acquired a new position in Biohaven during the second quarter valued at approximately $125,000. Cypress Wealth Services LLC acquired a new position in Biohaven during the third quarter valued at approximately $224,000. Diversified Trust Co bought a new stake in Biohaven in the third quarter valued at approximately $239,000. Finally, Quarry LP raised its stake in Biohaven by 614.3% in the second quarter. Quarry LP now owns 5,000 shares of the company’s stock valued at $174,000 after buying an additional 4,300 shares during the period. 88.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on BHVN shares. Robert W. Baird upped their price objective on Biohaven from $58.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, September 23rd. UBS Group dropped their price objective on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. JPMorgan Chase & Co. upped their price objective on Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a research note on Thursday, October 3rd. HC Wainwright restated a “buy” rating and issued a $59.00 price objective on shares of Biohaven in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group started coverage on Biohaven in a research note on Monday, September 16th. They issued a “buy” rating and a $57.00 price objective on the stock. Thirteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $61.92.

Insiders Place Their Bets

In related news, Director John W. Childs acquired 21,052 shares of the stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the purchase, the director now directly owns 21,052 shares in the company, valued at approximately $999,970. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Biohaven news, Director Gregory Bailey bought 5,000 shares of Biohaven stock in a transaction on Tuesday, September 24th. The shares were purchased at an average price of $44.19 per share, with a total value of $220,950.00. Following the acquisition, the director now owns 1,620,071 shares in the company, valued at $71,590,937.49. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John W. Childs bought 21,052 shares of Biohaven stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the acquisition, the director now owns 21,052 shares in the company, valued at approximately $999,970. The disclosure for this purchase can be found here. Corporate insiders own 16.00% of the company’s stock.

Biohaven Price Performance

Biohaven stock opened at $50.86 on Friday. The stock’s fifty day moving average price is $45.69 and its two-hundred day moving average price is $40.14. Biohaven Ltd. has a one year low of $26.80 and a one year high of $62.21. The firm has a market cap of $4.81 billion, a PE ratio of -5.56 and a beta of 1.31.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). Sell-side analysts expect that Biohaven Ltd. will post -8.81 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.